Form 4: Avadel Pharmaceuticals CFO Acquires 5,000 Shares in Open Market Transaction

Avadel Pharmaceuticals' Chief Financial Officer, Thomas S. McHugh, purchased 5,000 ordinary shares at a price of $10.4865 per share on December 11, 2024.

Summary

• Thomas S. McHugh, the Chief Financial Officer of Avadel Pharmaceuticals, acquired 5,000 ordinary shares of the company.
• The transaction occurred on December 11, 2024.
• The shares were purchased at a price of $10.4865 per share.
• Following the transaction, Mr. McHugh directly owns 85,500 ordinary shares.

Sentiment

Score: 6

Explanation: The document reflects a routine insider transaction. While the purchase is a positive sign, it's not a major event that would significantly impact sentiment.

Positives

• The purchase of shares by a company executive can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. It provides transparency into the transactions of company executives.

Comparison to Industry Standards

• SEC Form 4 filings are standard practice for publicly traded companies in the United States.
• Similar filings are made by executives at companies like Amgen, Biogen, and Gilead Sciences when they trade their company's stock.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the CFO's purchase.

Key Dates

Keywords

Avadel Pharmaceuticals, Thomas S. McHugh, share purchase, insider trading, CFO, ordinary shares, SEC Form 4